MarketMoodz
Kodiak Sciences hits 52-week high on Zenkuda Phase 3 gains, BLA in view
Kodiak Sciences stock climbed to a 52-week high after GLOW2 topline data for Zenkuda showed strong efficacy in diabetic retinopathy. With a Biologics License Application underway, investors are eyeing a near-term regulatory catalyst and potential expansion of indications.
Key Takeaways
- Zenkuda (tarcocimab tedromer) delivered a ≥2-step DRSS improvement in 62.5% of patients vs 3.3% with sham.
- The primary efficacy signal included an ~85% relative risk reduction in the development of sight-threatening complications (2.4% vs 15.8%).
- Zenkuda achieved a ≥3-step DRSS improvement of 13.7% vs 0% for sham.
- A BLA submission plan is underway, signaling a near-term regulatory catalyst if results hold.
- Kodiak traded around $34.63 and hit a 52-week high; analysts' targets vary, with consensus at $15.71 and upside bets at UBS $50 and HC Wainwright $38.
People Involved
- Victor PerlrothChief Executive Officer, Kodiak Sciences
Entities Involved
- Kodiak SciencesBiopharmaceutical company developing Zenkuda (tarcocimab tedromer)
- Zenkuda (tarcocimab tedromer)Investigational therapy for diabetic retinopathy
- GLOW2 Phase 3 studyPhase 3 trial evaluating Zenkuda for diabetic retinopathy
MarketMoodz Analysis
Investors are getting a data-driven read on Zenkuda's potential. The topline results from GLOW2 show statistically significant improvement on the top DRSS endpoint and a durable signal on a key safety/secondary endpoint, supporting a near-term BLA submission. If durability holds and the safety profile remains favorable, the near-term regulatory catalyst could lift Kodiak's multiple and unlock upside from a high-beta biotech position.
Historically, positive Phase 3 data followed by a BLA submission tends to be a catalyst but not a guarantee; investors should gauge durability across full datasets and monitor any safety signal shifts as more patients are followed. Kodiak's stock has shown sensitivity to data news, and the wide dispersion in analyst targets (from about $15.71 to $50) highlights the risk-reward and the need for caution around valuation versus near-term catalysts.
What to watch next includes the durability of efficacy signals with longer follow-up, complete safety data, timing and process details for the BLA submission, and updates on pipeline expansion and other Phase 3 programs that could support a broader multi-indication, BLA-ready profile.
Source: Original Article